论文部分内容阅读
目的:观察卡铂加高聚生胸腹腔灌注治疗急性胸腹腔积液的疗效和毒副作用。方法:对45例急性胸腹腔积液患者(19例为恶性胸腔积液,26例为急性腹腔积液)随机分为卡铂单药组(对照组)与卡铂加高聚生组(治疗组)进行疗效观察。尽可能抽尽胸腹腔积液后,治疗组:胸腔每次注入卡铂500 mg~600 mg加高聚生4 000 U。对照组:单用卡铂500 mg~600 mg,每周注射1次,最多不超过3次,观察其疗效和毒副作用。结果:治疗组对恶性胸腹腔积液的有效率为91.3 %,对照组为54.5 %,治疗组主要不良反应为低热,对血象及肝肾功能无影响,对照组Ⅰ度~Ⅱ度骨髓抑制有5/22例。结论:卡铂加高聚生治疗恶性胸腹腔积液疗效好、副作用轻,值得临床上推广应用。
Objective: To observe the curative effect and side effects of carboplatin hyperactivity thoracic cavity peritoneal perfusion in the treatment of acute pleural effusion. Methods: Forty-five patients with acute pleural and peritoneal effusion (19 with malignant pleural effusion and 26 with acute ascites) were randomly divided into carboplatin monotherapy group (control group) and carboplatin hypercondensation group (treatment group) Efficacy of observation. Aspiration of ascites and ascites fluid as possible, the treatment group: each injection of carboplatin 500 ~ 600 mg hyperplasia 4,000 U. Control group: carboplatin alone 500 mg ~ 600 mg, once a week, up to no more than 3 times to observe the efficacy and side effects. Results: The effective rate of malignant pleural and peritoneal effusion was 91.3% in the treatment group and 54.5% in the control group. The main adverse reactions in the treatment group were low fever, which had no effect on blood and liver and kidney function. In the control group, 5/22 cases. Conclusion: Hyperplasia carboplatin in the treatment of malignant pleural and peritoneal effusion has good curative effect and light side effects, which is worth popularizing and applying clinically.